Browse > Article
http://dx.doi.org/10.4110/in.2015.15.3.135

Alloferon Alleviates Dextran Sulfate Sodium-induced Colitis  

Kim, Hyemin (Department of Anatomy, Seoul National University College of Medicine)
Im, Jong Pil (Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine)
Kim, Joo Sung (Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine)
Kang, Jae Seung (Department of Anatomy, Seoul National University College of Medicine)
Lee, Wang Jae (Department of Anatomy, Seoul National University College of Medicine)
Publication Information
IMMUNE NETWORK / v.15, no.3, 2015 , pp. 135-141 More about this Journal
Abstract
Dysfunction of gut immune regulation is involved in mucosal damage in inflammatory bowel disease (IBD). However, there is still no efficacious immune-regulator for the treatment of IBD. Alloferon is a novel immune-modulatory peptide that was originally isolated from infected insects. It shows anti-inflammatory effects by the regulation of cytokine production by immune cells and their activities. Therefore, we investigated the effect of alloferon in a mouse model of colitis using dextran sulfate sodium (DSS). Colitis was induced by administration of DSS in drinking water for 7 consecutive days. It was confirmed by the presence of weight loss, diarrhea, hematochezia, and colon contraction. Alloferon was injected 4 days after DSS administration. We found that alloferon improved the pathogenesis of IBD based on the reduced disease activity index (DAI) and colon contraction. Edema, epithelial erosion, and immune cell infiltration were found in mice administered DSS, but the phenomena were reduced following alloferon treatment. The plasma level of IL-6, a classical pro-inflammatory cytokine in colitis, was also decreased by alloferon. Moreover, alloferon inhibited the TNF-${\alpha}$-induced degradation and phosphorylation of $I{\kappa}B$ in Colo205 colon cancer cells. Taken together, these results show that alloferon has anti-inflammatory effects and attenuates DSS-induced colitis.
Keywords
Alloferon; Inflammatory bowel disease (IBD); Anti-inflammation; DSS-induced colitis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Xavier, R. J., and D. K. Podolsky. 2007. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427-434.   DOI
2 Baumgart, D. C., and W. J. Sandborn. 2007. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369: 1641-1657.   DOI
3 Thia, K. T., E. V. Loftus, Jr., W. J. Sandborn, and S. K. Yang. 2008. An update on the epidemiology of inflammatory bowel disease in Asia. Am. J .Gastroenterol. 103: 3167-3182.   DOI
4 Yang, S. K., S. Yun, J. H. Kim, J. Y. Park, H. Y. Kim, Y. H. Kim, D. K. Chang, J. S. Kim, I. S. Song, J. B. Park, E. R. Park, K. J. Kim, G. Moon, and S. H. Yang. 2008. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm. Bowel. Dis. 14: 542-549.   DOI
5 Chernysh, S., K. Irina, and A. Irina. 2012. Anti-tumor activity of immunomodulatory peptide alloferon-1 in mouse tumor transplantation model. Int. Immunopharmacol. 12: 312-314.   DOI
6 Lee, N., S. Bae, H. Kim, J. M. Kong, H. R. Kim, B. J. Cho, S. J. Kim, S. H. Seok, Y. I. Hwang, S. Kim, J. S. Kang, and W. J. Lee. 2011. Inhibition of lytic reactivation of Kaposi's sarcoma- associated herpesvirus by alloferon. Antivir. Ther. 16: 17-26.   DOI
7 Bae, S., K. Oh, H. Kim, Y. Kim, H. R. Kim, Y. I. Hwang, D. S. Lee, J. S. Kang, and W. J. Lee. 2013. The effect of alloferon on the enhancement of NK cell cytotoxicity against cancer via the up-regulation of perforin/granzyme B secretion. Immunobiology 218: 1026-1033.   DOI
8 Kim, Y., S. K. Lee, S. Bae, H. Kim, Y. Park, N. K. Chu, S. G. Kim, H. R. Kim, Y. I. Hwang, J. S. Kang, and W. J. Lee. 2013. The anti-inflammatory effect of alloferon on UVB-induced skin inflammation through the down-regulation of pro-inflammatory cytokines. Immunol. Lett. 149: 110-118.   DOI
9 Sander, L. E., F. Obermeier, U. Dierssen, D. C. Kroy, A. K. Singh, U. Seidler, K. L. Streetz, H. H. Lutz, W. Muller, F. Tacke, and C. Trautwein. 2008. Gp130 signaling promotes development of acute experimental colitis by facilitating early neutrophil/macrophage recruitment and activation. J. Immunol. 181: 3586-3594.   DOI
10 Lin, Y., X. Yang, W. Yue, X. Xu, B. Li, L. Zou, and R. He. 2014. Chemerin aggravates DSS-induced colitis by suppressing M2 macrophage polarization. Cell. Mol. Immunol. 11: 355-366.   DOI
11 Li, B., R. Alli, P. Vogel, and T. L. Geiger. 2014. IL-10 modulates DSS-induced colitis through a macrophage-ROS-NO axis. Mucosal Immunol. 7: 869-878.   DOI
12 Jarry, A., C. Bossard, C. Bou-Hanna, D. Masson, E. Espaze, M. G. Denis, and C. L. Laboisse. 2008. Mucosal IL-10 and TGF-beta play crucial roles in preventing LPS-driven, IFN-gamma-mediated epithelial damage in human colon explants. J. Clin. Invest. 118: 1132-1142.
13 Marrero, J. A., K. A. Matkowskyj, K. Yung, G. Hecht, and R. V. Benya. 2000. Dextran sulfate sodium-induced murine colitis activates NF-kappaB and increases galanin-1 receptor expression. Am. J. Physiol. Gastrointest. Liver Physiol. 278: G797-G804.   DOI
14 Andresen, L., V. L. Jorgensen, A. Perner, A. Hansen, J. Eugen-Olsen, and J. Rask-Madsen. 2005. Activation of nuclear factor kappaB in colonic mucosa from patients with collagenous and ulcerative colitis. Gut 54: 503-509.   DOI
15 Rogler, G., K. Brand, D. Vogl, S. Page, R. Hofmeister, T. Andus, R. Knuechel, P. A. Baeuerle, J. Scholmerich, and V. Gross. 1998. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 115: 357-369.   DOI
16 Kanarek, N., N. London, O. Schueler-Furman, and Y. Ben-Neriah. 2010. Ubiquitination and degradation of the inhibitors of NFkappaB. Cold Spring Harb. Perspect. Biol. 2: a000166.
17 Chernysh, S., and N. Gordja. 2011. The immune system of maggots of the blow fly (Calliphora vicina) as a source of medicinal drugs. J. Evol. Biochem. Physiol. 47: 524-533.   DOI
18 Hanauer, S. B. 2006. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm. Bowel. Dis. 12 Suppl 1: S3-S9.
19 Molodecky, N. A., I. S. Soon, D. M. Rabi, W. A. Ghali, M. Ferris, G. Chernoff, E. I. Benchimol, R. Panaccione, S. Ghosh, H. W. Barkema, and G. G. Kaplan. 2012. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142: 46-54.   DOI
20 Ershov, F., A. Kubanova, B. Pinegin, A. Shulzhenko, G. Bekker, and S. Chernysh. 2003. Allokine-$\alpha$ effect on the course of chronic genital herpes relapses. Materia Medica 40: 103-111.
21 Taylor, B. S., M. E. de Vera, R. W. Ganster, Q. Wang, R. A. Shapiro, S. M. Morris, Jr., T. R. Billiar, and D. A. Geller. 1998. Multiple NF-kappaB enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene. J. Biol. Chem. 273: 15148-15156.   DOI
22 Neurath, M. F., S. Finotto, I. Fuss, M. Boirivant, P. R. Galle, and W. Strober. 2001. Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question. Trends Immunol. 22: 21-26.   DOI
23 Grivennikov, S., E. Karin, J. Terzic, D. Mucida, G. Y. Yu, S. Vallabhapurapu, J. Scheller, S. Rose-John, H. Cheroutre, L. Eckmann, and M. Karin. 2009. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15: 103-113.   DOI
24 Jin, X., T. A. Zimmers, Z. Zhang, R. H. Pierce, and L. G. Koniaris. 2010. Interleukin-6 is an important in vivo inhibitor of intestinal epithelial cell death in mice. Gut 59: 186-196.   DOI
25 Kraus, T. A., L. Toy, L. Chan, J. Childs, A. Cheifetz, and L. Mayer. 2004. Failure to induce oral tolerance in Crohn's and ulcerative colitis patients: possible genetic risk. Ann. N. Y. Acad. Sci. 1029: 225-238.   DOI
26 Triantafillidis, J. K., G. Nasioulas, and P. A. Kosmidis. 2009. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res. 29: 2727-2737.
27 Ryu, M. J., V. Anikin, S. H. Hong, H. Jeon, Y. G. Yu, M. H. Yu, S. Chernysh, and C. Lee. 2008. Activation of NF-kappaB by alloferon through down-regulation of antioxidant proteins and IkappaBalpha. Mol. Cell. Biochem. 313: 91-102.   DOI
28 Cheng, M., Y. Chen, W. Xiao, R. Sun, and Z. Tian. 2013. NK cell-based immunotherapy for malignant diseases. Cell. Mol.Immunol. 10: 230-252.   DOI
29 Chandel, N. S., W. C. Trzyna, D. S. McClintock, and P. T. Schumacker. 2000. Role of oxidants in NF-kappa B activation and TNF-alpha gene transcription induced by hypoxia and endotoxin. J. Immunol. 165: 1013-1021.   DOI
30 Chernysh, S., S. I. Kim, G. Bekker, V. A. Pleskach, N. A. Filatova, V. B. Anikin, V. G. Platonov, and P. Bulet. 2002. Antiviral and antitumor peptides from insects. Proc. Natl. Acad. Sci. U. S. A. 99: 12628-12632.   DOI
31 Lee, M. J., J. K. Lee, J. W. Choi, C. S. Lee, J. H. Sim, C. H. Cho, K. H. Lee, I. H. Cho, M. H. Chung, H. R. Kim, and S. K. Ye. 2012. Interleukin-6 induces S100A9 expression in colonic epithelial cells through STAT3 activation in experimental ulcerative colitis. PLoS One 7: e38801.   DOI